Estonya - Estonca - Ravimiamet

sandoz pharmaceuticals d.d. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 28tk

Estonya - Estonca - Ravimiamet

stada arzneimittel ag - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk; 14mg 84tk

Estonya - Estonca - Ravimiamet

krka, d.d., novo mesto - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 14tk; 14mg 98tk; 14mg 28tk; 14mg 30tk

Estonya - Estonca - Ravimiamet

gedeon richter plc. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk; 14mg 14tk; 14mg 98tk; 14mg 84tk

Estonya - Estonca - Ravimiamet

zentiva k.s. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 14tk; 14mg 28tk; 14mg 84tk

Estonya - Estonca - Ravimiamet

norameda uab - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk

Estonya - Estonca - Ravimiamet

teva b.v. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 14tk; 14mg 28tk; 14mg 30tk; 14mg 84tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

biogen netherlands b.v. - natalisumab - hulgiskleroos - selektiivsed immunosupressandid - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - sclerosis multiplex, relapsing-remitting - immunosupressandid - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

sandoz gmbh - natalisumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.